| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-06 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-06 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.14 | 5e-06 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-06 |